The biotech turned an operating profit in the fourth quarter thanks to revenue from partners.
News & Analysis: Ionis Pharmaceuticals
IONS earnings call for the period ending December 31, 2018.
Fourth-quarter earnings exceed expectations.
Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.
Earnings per share will more than double for each of these specialty drugmakers.
With $2 billion in the bank, the biotech can afford to invest in the future.
IONS earnings call for the period ending September 30, 2018.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
A surprise rejection is a major setback for both partners, but not the end of the line.
Find out what investors are worried about with these stocks.